{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 14 December 2005\line \line {\b Changes 
on Corporate 
Executive Committee and Board of Directors of Roche} \line \line Heino von Prondzynski, 
CEO Division Roche Diagnostics, has decided to retire from his executive functions in the course of 
next year in order to pursue personal interests. At its last meeting, the Board of Directors of Roche 
has appointed Severin Schwan as the new CEO Division Roche Diagnostics and as a member of the Corporate 
Executive Committee, effective 1 January, 2006. Severin Schwan is currently regional head Asia-Pacific 
of Roche Diagnostics. \line \line Also, per 1 January, 2006, Burkhard G. Piper is 
appointed as a member of the Enlarged Corporate Executive Committee. Burkhard G. Piper was recently 
appointed head of the diagnostics business unit Roche Diabetes Care following the retirement of Staffan 
Ek. \line \line As of 1 January, 2006, the Corporate Executive Committee (CEC) of 
Roche will have the following composition:\line \par}{\pard
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl {\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Corporate Executive Committee:} \par} \cell
\pard\intbl  \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Franz B. Humer (1946) \cell
\pard\intbl Chairman and CEO of the Roche Group \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Erich 
Hunziker (1953) \cell
\pard\intbl Chief Financial Officer, Deputy Head of the Corporate Executive Committee \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl William 
Burns (1947) \cell
\pard\intbl CEO Division Roche Pharma \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Severin Schwan (1967) \cell
\pard\intbl CEO Division 
Roche Diagnostics \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Jonathan Knowles (1947) \cell
\pard\intbl Head Global Research \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Gottlieb 
Keller (1954) \cell
\pard\intbl Head Corporate Services and Human Resources \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl  \cell
\pard\intbl  \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl {\b Enlarged 
Corporate Executive Committee:}  \cell
\pard\intbl  \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Ed Holdener (1945) \cell
\pard\intbl Head Global Pharma Development \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Peter 
Hug (1958) \cell
\pard\intbl Head Pharma Partnering \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Burkhard G. Piper (1961) \cell
\pard\intbl Head Business Unit Roche 
Diabetes Care \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Rolf Schl\u228?pfer (1956) \cell
\pard\intbl Head Corporate Communications \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Osamu 
Nagayama (1947) \cell
\pard\intbl President and CEO Chugai \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl  \cell
\pard\intbl  \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl {\b Secretary to the Corporate Executive 
Committee:}  \cell
\pard\intbl  \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Pierre Jaccoud (1955)  \cell
\pard\intbl Head Chairman\u8217?s Office \cell
\row
}{\pard\f0\li0\ri0\sa360\sl360\fs22 Franz 
B. Humer, Chairman and CEO von Roche: \u8222?For many years, Heino von Prondzynski has significantly contributed 
to the outstanding success of our Diagnostics division. Under his leadership the Division has substantially 
strengthened its global No 1 position and we express our deep gratitude to him for his distinguished 
service. With the appointment of Severin Schwan and Burkhard G. Piper we continue to rejuvenate 
our senior leadership team with highly qualified Roche managers.\u8220? \line \line {\b Changes 
on Board of Directors} \line At the Annual General Meeting (AGM) on 27 February, 2006 
the regular 
terms of Rolf H\u228?nggi, Peter Brabeck-Letmathe, DeAnne Julius and Prof. Horst Teltschik will end. The 
Board of Directors proposes to the AGM the re-election of Peter Brabeck-Letmathe, DeAnne Julius and 
Prof. Horst Teltschik as members of the Board of Directors of Roche for another term of four years. 
\line \line Rolf H\u228?nggi who served the Board of Directors as its Vice President 
since 1996 has announced his intention not to stand for re-election. The Board of Directors proposes 
to the AGM the election of Prof. Beatrice Weder di Mauro as a new Board member. \line \line {\b Curricula 
vitae} \line Swiss national Beatrice Weder di Mauro was born 1965 in Basel. Since 2001 
she is 
a professor of economics at the University of Mainz and since August 2004, she is a member of the German 
Council of Economic Experts. Previously she worked as an economist at the International Monetary Fund 
and at the World Bank, Washington. She holds a PhD from the University of Basel.\line \line The 
Austrian Severin Schwan, born 1967, graduated in economics and also holds a doctorate in law. His career 
with Roche began in 1993 at the Corporate Finance department in Basle. After various international positions 
Severin Schwan became Head of Global Finance & Services for Roche Diagnostics, before he took over 
as Head of Region Asia Pacific for the Diagnostics division.\line \line Burkhard 
G. Piper, a German by nationality, was born 1961 and has a Diploma in industrial economics. He started 
his business career in 1985 with Boehringer Mannheim, a healthcare company which was later acquired 
by Roche. After several management positions in marketing he was appointed General Manager of Roche 
Diagnostics Canada in 1999. In 2002 Burkhard Piper took over the position as Head Centralized Diagnostics 
and since 2005 he leads the Business Unit Roche Diabetes Care. \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused 
healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products 
and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes 
on a broad range of fronts to improving people\u8217?s health and quality of life. Roche is a world leader 
in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader 
in virology. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic 
alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional 
information about the Roche Group is available on the Internet (www.roche.com (http://www.roche.com)).\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}